FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048489506> ?p ?o ?g. }

• W2048489506 endingPage "2432" @default.
• W2048489506 startingPage "2423" @default.
• W2048489506 abstract "Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.BackgroundPatients with acute renal failure (ARF) have high morbidity and mortality rates, particularly if they have serious comorbid conditions. Several studies indicate that in rats with ARF caused by ischemia or certain nephrotoxins, insulin-like growth factor-I (IGF-I) enhances the recovery of renal function and suppresses protein catabolism.MethodsOur objective was to determine whether injections of recombinant human IGF-I (rhIGF-I) would enhance the recovery of renal function and is safe in patients with ARF. The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals. Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients). The most common causes of ARF in the rhIGF-I and placebo groups were, respectively, sepsis (37 and 35% of patients) and hypotension or hemodynamic shock (42 and 27% of patients). At baseline, the mean (± sd) APACHE II scores in the rhIGF-I and placebo-treated groups were 24 ± 5 and 25 ± 8, respectively. In the rhIGF-I and placebo groups, the mean (median) urine volume and urinary iothalamate clearances (glomerular filtration rate) were 1116 ± 1037 (887) and 1402 ± 1183 (1430) ml/24 hr and 6.4 ± 5.9 (4.3) and 8.7 ± 7.2 (4.4) ml/min and did not differ between the two groups. Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 μg/kg desirable body weight, or placebo for up to 14 days. Injections were started within six days of the onset of ARF. The primary end-point was a change in glomerular filtration rate from baseline. Other end points included changes from baseline in urine volume, creatinine clearance and serum urea, creatinine, albumin and transferrin, frequency of hemodialysis or ultrafiltration, and mortality rate.ResultsDuring the treatment period, which averaged 10.7 ± 4.1 and 10.6 ± 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin. In patients who did not receive renal replacement therapy, there was also no significant difference in serum creatinine and urea between the two groups. Twenty patients in the rhIGF-I group and 17 placebo-treated patients underwent dialysis or ultrafiltration. Twelve rhIGF-I–treated patients and 12 placebo-treated patients died during the 28 days after the onset of treatment.ConclusionsrhIGF-I does not accelerate the recovery of renal function in ARF patients with substantial comorbidity. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Patients with acute renal failure (ARF) have high morbidity and mortality rates, particularly if they have serious comorbid conditions. Several studies indicate that in rats with ARF caused by ischemia or certain nephrotoxins, insulin-like growth factor-I (IGF-I) enhances the recovery of renal function and suppresses protein catabolism. Our objective was to determine whether injections of recombinant human IGF-I (rhIGF-I) would enhance the recovery of renal function and is safe in patients with ARF. The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals. Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients). The most common causes of ARF in the rhIGF-I and placebo groups were, respectively, sepsis (37 and 35% of patients) and hypotension or hemodynamic shock (42 and 27% of patients). At baseline, the mean (± sd) APACHE II scores in the rhIGF-I and placebo-treated groups were 24 ± 5 and 25 ± 8, respectively. In the rhIGF-I and placebo groups, the mean (median) urine volume and urinary iothalamate clearances (glomerular filtration rate) were 1116 ± 1037 (887) and 1402 ± 1183 (1430) ml/24 hr and 6.4 ± 5.9 (4.3) and 8.7 ± 7.2 (4.4) ml/min and did not differ between the two groups. Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 μg/kg desirable body weight, or placebo for up to 14 days. Injections were started within six days of the onset of ARF. The primary end-point was a change in glomerular filtration rate from baseline. Other end points included changes from baseline in urine volume, creatinine clearance and serum urea, creatinine, albumin and transferrin, frequency of hemodialysis or ultrafiltration, and mortality rate. During the treatment period, which averaged 10.7 ± 4.1 and 10.6 ± 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin. In patients who did not receive renal replacement therapy, there was also no significant difference in serum creatinine and urea between the two groups. Twenty patients in the rhIGF-I group and 17 placebo-treated patients underwent dialysis or ultrafiltration. Twelve rhIGF-I–treated patients and 12 placebo-treated patients died during the 28 days after the onset of treatment. rhIGF-I does not accelerate the recovery of renal function in ARF patients with substantial comorbidity." @default.
• W2048489506 created "2016-06-24" @default.
• W2048489506 creator A5000486241 @default.
• W2048489506 creator A5003967548 @default.
• W2048489506 creator A5012229337 @default.
• W2048489506 creator A5014239086 @default.
• W2048489506 creator A5015636761 @default.
• W2048489506 creator A5017432390 @default.
• W2048489506 creator A5018437086 @default.
• W2048489506 creator A5024564695 @default.
• W2048489506 creator A5029720798 @default.
• W2048489506 creator A5033971650 @default.
• W2048489506 creator A5034404247 @default.
• W2048489506 creator A5041237897 @default.
• W2048489506 creator A5048014973 @default.
• W2048489506 creator A5050491175 @default.
• W2048489506 creator A5052310815 @default.
• W2048489506 creator A5053734129 @default.
• W2048489506 creator A5055706380 @default.
• W2048489506 creator A5058940883 @default.
• W2048489506 creator A5060074541 @default.
• W2048489506 creator A5062858471 @default.
• W2048489506 creator A5075302749 @default.
• W2048489506 creator A5081967003 @default.
• W2048489506 creator A5082370453 @default.
• W2048489506 creator A5083506618 @default.
• W2048489506 creator A5087036967 @default.
• W2048489506 creator A5088990210 @default.
• W2048489506 creator A5089452946 @default.
• W2048489506 date "1999-06-01" @default.
• W2048489506 modified "2023-10-14" @default.
• W2048489506 title "Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure" @default.
• W2048489506 cites W1969121572 @default.
• W2048489506 cites W1971581415 @default.
• W2048489506 cites W1978636119 @default.
• W2048489506 cites W1993782115 @default.
• W2048489506 cites W1998272315 @default.
• W2048489506 cites W1999801514 @default.
• W2048489506 cites W2003004549 @default.
• W2048489506 cites W2014792180 @default.
• W2048489506 cites W2020882360 @default.
• W2048489506 cites W2024067973 @default.
• W2048489506 cites W2034230657 @default.
• W2048489506 cites W2037887467 @default.
• W2048489506 cites W2043664888 @default.
• W2048489506 cites W2063123103 @default.
• W2048489506 cites W2077695184 @default.
• W2048489506 cites W2078481606 @default.
• W2048489506 cites W2082355794 @default.
• W2048489506 cites W2085347646 @default.
• W2048489506 cites W2085604023 @default.
• W2048489506 cites W2128129109 @default.
• W2048489506 cites W2134109634 @default.
• W2048489506 cites W2166687975 @default.
• W2048489506 cites W2256950830 @default.
• W2048489506 cites W2272732540 @default.
• W2048489506 cites W2345773209 @default.
• W2048489506 cites W2408863301 @default.
• W2048489506 cites W4313315460 @default.
• W2048489506 doi "https://doi.org/10.1046/j.1523-1755.1999.00463.x" @default.
• W2048489506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10354291" @default.
• W2048489506 hasPublicationYear "1999" @default.
• W2048489506 type Work @default.
• W2048489506 sameAs 2048489506 @default.
• W2048489506 citedByCount "284" @default.
• W2048489506 countsByYear W20484895062012 @default.
• W2048489506 countsByYear W20484895062013 @default.
• W2048489506 countsByYear W20484895062014 @default.
• W2048489506 countsByYear W20484895062015 @default.
• W2048489506 countsByYear W20484895062016 @default.
• W2048489506 countsByYear W20484895062017 @default.
• W2048489506 countsByYear W20484895062018 @default.
• W2048489506 countsByYear W20484895062019 @default.
• W2048489506 countsByYear W20484895062020 @default.
• W2048489506 countsByYear W20484895062021 @default.
• W2048489506 countsByYear W20484895062022 @default.
• W2048489506 countsByYear W20484895062023 @default.
• W2048489506 crossrefType "journal-article" @default.
• W2048489506 hasAuthorship W2048489506A5000486241 @default.
• W2048489506 hasAuthorship W2048489506A5003967548 @default.
• W2048489506 hasAuthorship W2048489506A5012229337 @default.
• W2048489506 hasAuthorship W2048489506A5014239086 @default.
• W2048489506 hasAuthorship W2048489506A5015636761 @default.
• W2048489506 hasAuthorship W2048489506A5017432390 @default.
• W2048489506 hasAuthorship W2048489506A5018437086 @default.
• W2048489506 hasAuthorship W2048489506A5024564695 @default.
• W2048489506 hasAuthorship W2048489506A5029720798 @default.
• W2048489506 hasAuthorship W2048489506A5033971650 @default.
• W2048489506 hasAuthorship W2048489506A5034404247 @default.
• W2048489506 hasAuthorship W2048489506A5041237897 @default.
• W2048489506 hasAuthorship W2048489506A5048014973 @default.
• W2048489506 hasAuthorship W2048489506A5050491175 @default.
• W2048489506 hasAuthorship W2048489506A5052310815 @default.
• W2048489506 hasAuthorship W2048489506A5053734129 @default.
• W2048489506 hasAuthorship W2048489506A5055706380 @default.
• W2048489506 hasAuthorship W2048489506A5058940883 @default.
• W2048489506 hasAuthorship W2048489506A5060074541 @default.
• W2048489506 hasAuthorship W2048489506A5062858471 @default.

• next